4BCG
Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor
4BCG の概要
| エントリーDOI | 10.2210/pdb4bcg/pdb |
| 関連するPDBエントリー | 1PF6 4BCF 4BCH 4BCI 4BCJ 4BCK 4BCM 4BCN 4BCO 4BCP 4BCQ |
| 分子名称 | CYCLIN-DEPENDENT KINASE 9, CYCLIN-T1, 2-[[3-(1,4-diazepan-1-yl)phenyl]amino]-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidine-5-carbonitrile, ... (5 entities in total) |
| 機能のキーワード | transferase-cell cycle complex, cdk-cyclin complex, transcription-protein binding, structure-based drug design, transferase/cell cycle |
| 由来する生物種 | HOMO SAPIENS (HUMAN) 詳細 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 68778.23 |
| 構造登録者 | Hole, A.J.,Baumli, S.,Wang, S.,Endicott, J.A.,Noble, M.E.M. (登録日: 2012-10-02, 公開日: 2013-04-17, 最終更新日: 2024-11-13) |
| 主引用文献 | Shao, H.,Shi, S.,Huang, S.,Hole, A.,Abbas, A.Y.,Baumli, S.,Liu, X.,Lam, F.,Foley, D.W.,Fischer, P.M.,Noble, M.,Endicott, J.A.,Pepper, C.,Wang, S. Substituted 4-(Thiazol-5-Yl)-2-(Phenylamino)Pyrimidines are Highly Active Cdk9 Inhibitors: Synthesis, X-Ray Crystal Structure, Sar and Anti-Cancer Activities. J.Med.Chem., 56:640-, 2013 Cited by PubMed Abstract: Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the C5-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC(50) = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper, (34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B- and T-cells. PubMed: 23301767DOI: 10.1021/JM301475F 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.085 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






